Provectus completes phase 1 metastatic melanoma clinical trial objectives

By Elaine Rigoli

Tampa, Fla., May 15 - Provectus Pharmaceuticals, Inc. announced that a second group of subjects has been treated in the company's phase 1 clinical trial of PV-10 for ablation of metastatic melanoma, an aggressive and often fatal form of skin cancer.

Treatment with PV-10 was well-tolerated by all subjects, with no evidence of systemic or serious local side effects. Most subjects have exhibited evidence of efficacy, ranging from tumor shrinkage to complete ablation.

Several also exhibited subsequent shrinkage of untreated tumors. These results achieve the primary study endpoints of safety and preliminary efficacy assessment, the company said in a news release.

Provectus has expanded the scope of the study to include a third group of subjects who will receive treatment of up to 20 melanoma lesions, the release said.

Located in Knoxville, Tenn., Provectus is a biopharmaceutical company that develops pharmaceutical technologies for the treatment of breast cancer, liver cancer and metastatic melanoma.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.